Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200011, China.
BMC Psychiatry. 2023 Mar 28;23(1):206. doi: 10.1186/s12888-023-04684-1.
We aimed to investigate the differences of metabolic disorders between the general population and psychiatric patients, with an emphasis on the prevalence and influencing factors of liver fibrosis in psychiatric patients.
A total of 734 psychiatric patients and 734 general population matched for age, sex, and BMI were enrolled from Shanghai, China. All participants underwent blood pressure, glucose, lipid profile measurements, and anthropometric parameters including body weight, height and waist circumference. FibroScan examinations were also performed on psychiatric patients. Liver steatosis and fibrosis were diagnosed by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by professional staff.
Compared with the general population, psychiatric patients revealed significantly higher burden of metabolic disorders. The overall prevalence of liver steatosis (CAP ≥ 233 dB/m) and fibrosis (LSM ≥ 7.0 kPa) was 48.7% and 15.5% in psychiatric patients. Psychiatric patients with liver steatosis or fibrosis showed worse metabolic profile. Meanwhile, the prevalence of liver fibrosis was also significantly higher in patients with overweight, central obesity, diabetes, hypertension, metabolic syndrome, and liver steatosis. In logistic regression analyses, age, BMI and visceral adiposity index were independent risk factors for liver fibrosis in psychiatric patients. Additionally, antipsychotic medication was suggested to be associated with an increased risk of liver fibrosis in psychiatric patients with liver steatosis.
Prevalence of liver steatosis and fibrosis is high in Chinese psychiatric patients. Those with antipsychotic polypharmacy and obesity are at high risk, and may benefit from early liver assessment in preventing fibrosis progression.
本研究旨在探讨一般人群与精神科患者代谢异常的差异,重点关注精神科患者肝纤维化的患病率及影响因素。
本研究共纳入 734 例精神科患者和 734 例年龄、性别和 BMI 相匹配的一般人群。所有参与者均接受血压、血糖、血脂谱测量以及体重、身高和腰围等人体测量参数检测。同时对精神科患者进行 FibroScan 检查。由专业人员通过受控衰减参数(CAP)和肝脏硬度测量(LSM)诊断肝脂肪变性和纤维化。
与一般人群相比,精神科患者的代谢异常负担明显更重。精神科患者肝脂肪变性(CAP≥233 dB/m)和纤维化(LSM≥7.0 kPa)的总患病率分别为 48.7%和 15.5%。患有肝脂肪变性或纤维化的精神科患者的代谢特征更差。同时,超重、中心性肥胖、糖尿病、高血压、代谢综合征和肝脂肪变性患者的肝纤维化患病率也显著更高。Logistic 回归分析显示,年龄、BMI 和内脏脂肪指数是精神科患者肝纤维化的独立危险因素。此外,抗精神病药物治疗被认为与伴有肝脂肪变性的精神科患者肝纤维化风险增加相关。
中国精神科患者肝脂肪变性和纤维化的患病率较高。使用多种抗精神病药物和肥胖的患者风险较高,可能需要早期进行肝脏评估以预防纤维化进展。